Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PREP | P48147 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL27630753 | 0.95 | USP2 (0.45) | USP2SMN1; SMN2PREPHPGDDPP4 | |
| SCHEMBL4773530 | 0.90 | USP2 (0.58) | USP2SMN1; SMN2HPGDGPR119MEN1 | |
| SCHEMBL4693378 | 0.89 | HPGD (0.46) | USP2SMN1; SMN2PREPHPGDGPR119 | |
| SCHEMBL2596349 | 0.89 | PTPN2 (0.48) | USP2SMN1; SMN2PREPGPR119MEN1 | |
| SCHEMBL15624132 | 0.88 | HPGD (0.49) | USP2SMN1; SMN2PREPHPGDCTSK | |
| SCHEMBL15624147 | 0.88 | HPGD (0.49) | USP2SMN1; SMN2PREPHPGDCTSK | |
| SCHEMBL17248133 | 0.86 | HPGD (0.51) | USP2SMN1; SMN2PREPHPGDCTSK | |
| SCHEMBL222920 | 0.86 | PREP (0.53) | USP2SMN1; SMN2PREPHPGDGPR119 | |
| SCHEMBL29877008 | 0.84 | USP2 (0.45) | USP2SMN1; SMN2PREPHPGDGPR119 | |
| SCHEMBL11913651 | 0.84 | USP2 (0.51) | USP2SMN1; SMN2HPGDGPR119MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 821 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118541362-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2024-08-23 | — | — | CN | claimed |
| CN-114829344-B | Pyrimidine derivatives and pharmaceutical compositions containing the same | 韩国化学研究院 | 2024-08-13 | — | — | CN | claimed |
| CN-114746411-B | Substituted tricyclic compounds | 印度鲁宾有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-114085219-B | Synthesis of (1S, 6R) -8-benzyl-7, 9-dioxo-2, 8-diazabicyclo [4.3.0] nonane | 武汉理工大学 | 2023-08-01 | — | — | CN | claimed |
| EP-3741757-B1 | DIHYDROINDOLIZINONE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2023-07-26 | — | — | EP | claimed |
| CN-114829344-A | Novel pyrimidine derivative and use thereof | 韩国化学研究院 | 2022-07-29 | — | — | CN | claimed |
| CN-114746411-A | Substituted tricyclic compounds | 印度鲁宾有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-114085219-A | Synthesis of (1S,6R) -8-benzyl-7, 9-dioxo-2, 8-diazabicyclo [4.3.0] nonane | 武汉理工大学 | 2022-02-25 | — | — | CN | claimed |
| CN-119528901-B | Thiazole compound, dessumo and/or deubiquitinase inhibitor, and preparation methods and applications thereof | Shanghai tongji hospital (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-12378232-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4587435-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS AND DEGRADERS | Cullgen (Shanghai), Inc. (CN) | 2025-07-23 | — | — | EP | disclosed |
| CN-120152967-A | Bifunctional compounds containing 2, 5-substituted pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 霖康疗法公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250171462-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| CN-115335373-B | Compounds and uses thereof | 福宏治疗公司 | 2025-05-20 | — | — | CN | disclosed |
| CN-1139928-A | Novel compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-01-08 | — | — | CN | disclosed |
| EP-0737193-A1 | PYRAZOLOPYRIDINE ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-16 | — | — | EP | disclosed |
| US-5554752-A | SPIRO FUSED PIPERIDINES CAPABLE OF BINDING TO A VESAMICOL RECEPTOR AND HAVING ANTICHOLINERGIC PROPERTIES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1996-09-10 | — | — | US | disclosed |
| US-5457207-A | Anticholinergic agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1995-10-10 | — | — | US | disclosed |
| WO-1995018128-A1 | PYRAZOLOPYRIDINE ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-06 | — | — | WO | disclosed |
| WO-1995009631-A1 | SPIROVESAMICOLS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171462-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SARM1, SARS1, TIAM1 | USP2 2412/4885SMN1; SMN2 774/4885PREP 2455/4885 |
| US-12378232-B2 | Cyclin dependent kinase inhibitors | CCNY, CCNI, CCNK | USP2 2158/4885SMN1; SMN2 4086/4885PREP 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.